levofloxacin has been researched along with Bacterial Pneumonia in 115 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (6.09) | 18.2507 |
| 2000's | 71 (61.74) | 29.6817 |
| 2010's | 35 (30.43) | 24.3611 |
| 2020's | 2 (1.74) | 2.80 |
| Authors | Studies |
|---|---|
| Cosler, L; Gupta, R; Kwa, A; Lodise, TP; Smith, RP | 1 |
| Bao, L; Cao, S; Chen, M; Cui, X; Guo, S; Pang, B; Sun, J; Sun, Q; Wang, Y; Xu, Y; Zhang, J; Zhang, Y; Zhao, R | 1 |
| Alishlash, AS; Atkinson, TP; Leal, SM; Schlappi, C; Waites, KB; Xiao, L | 1 |
| Bai, X; Dong, X; Gao, J; Guo, T; Hao, S; He, F; Li, Q; Tan, S; Yang, J | 1 |
| Aslan, S; Aykent, A; Ignak, S; Karadağ, G; Soydan, S; Unay Demirel, O | 1 |
| Alhabshan, RN; Mansour, TN | 1 |
| Bulkow, L; Gordon, K; Stevens, R; Westley, B | 1 |
| Cao, Z; Chang, L; Cheng, SL; Lv, Y; Ma, Z; Mo, B; Sun, S; Tong, Z; Wu, J; Wu, R; Yang, Y; Yuan, J; Zhang, Y; Zhu, D | 1 |
| Hatakeyama, S; Matsui, H; Morisawa, Y; Sasabuchi, Y; Sasahara, T; Suzuki, J; Yamada, T; Yasunaga, H | 1 |
| Briales, A; Díaz-de-Alba, P; Docobo-Pérez, F; Domínguez-Herrera, J; López-Rojas, R; Pachón, J; Pascual, A; Pichardo, C; Rodríguez-Baño, J; Rodríguez-Martínez, JM; Velasco, C | 1 |
| Clark, K; Craft, JC; Das, A; Fernandes, P; Jamieson, BD; Oldach, D; Schranz, J; Scott, D | 1 |
| Agnello, M; Bensman, J; Lou, M; Shriner, K; Sullivan, E; Wong-Beringer, A | 1 |
| Chen, JC; Kuo, CW; Lin, CC; Tsai, LH; Weng, YM | 1 |
| Fang, X; Gong, M; Xia, J; Xu, Y; Zhang, D; Zhou, Y | 1 |
| Kadota, J; Kakeya, H; Kawanami, T; Kohno, S; Mukae, H; Tokimatsu, I; Yamamoto, Y; Yanagihara, K; Yatera, K | 1 |
| Huang, JA; Lv, XJ; Si, B; Sun, SH; Wang, C; Wu, JF; Xiao, ZK; Xie, CM; Xiu, QY; Zhang, DP; Zhang, YY; Zhao, X | 1 |
| Chen, YH; Hsueh, PR; Huang, CH; Lai, CC | 1 |
| Lee, CH; Lee, LN; Lee, MC; Wang, JT; Wang, JY; Yu, MC | 1 |
| Babarina, MB; Sokolova, VI; Sychev, DA; Zaikov, DA | 1 |
| Ariza-Prota, MA; Budiño, T; Casan, P; Fole-Vázquez, D; García-Clemente, M; Pando-Sandoval, A | 1 |
| Cojutti, P; Cotta, MO; Della Rocca, G; Lugano, M; Pea, F; Roberts, JA | 1 |
| Cao, Z; Chang, L; Chen, P; Cui, S; Hu, C; Kuang, J; Li, J; Liang, Y; Liu, H; Liu, S; Liu, Y; Lv, X; Lv, Y; Ren, Z; Sun, S; Wang, C; Wang, D; Wang, X; Wu, J; Xiao, Z; Xiu, Q; Yang, H; Zhang, Y; Zhao, L; Zhu, D | 1 |
| Etoh, Y; Furusyo, N; Hayashi, J; Kishihara, Y; Kumade, E; Mitsumoto-Kaseida, F; Murata, M; Takeshima, N | 1 |
| Crocetta, V; Di Bonaventura, G; Pompilio, A; Verginelli, F | 1 |
| Bergallo, C; Cooper, CA; Dartois, N; Dukart, G; Gandjini, H; Jasovich, A; Mallick, R; Oliva, ME; Tanaseanu, C; Teglia, O | 1 |
| Docobo-Pérez, F; García, I; Martínez-Martínez, L; Pachón, J; Pachón-Ibañez, ME; Pascual, A; Pichardo, C; Rodríguez-Martínez, JM | 1 |
| Gea-Banacloche, JC; Green, O; Murray, P | 1 |
| Bergallo, C; Cooper, A; de Wouters, L; Dukart, G; Jasovich, A; Lentnek, A; Mallick, R; Oliva, ME; Teglia, O; Zlocowski, JC | 1 |
| Castaing, N; Cooper, A; Dartois, N; Gandjini, H | 1 |
| Fisher, AC; Peterson, J; Yektashenas, B | 1 |
| Kozlov, RS; Riabkova, EL | 1 |
| Beloborodov, VB | 1 |
| Rapp, RP | 1 |
| Calistru, PI; Castaing, N; Chernyak, V; Cooper, CA; Dartois, N; Gandjini, H; Milutinovic, S; Strausz, J; Tanaseanu, C; Zolubas, M | 1 |
| Chi, CL; Chuang, TY; Hsueh, PR; Lee, SW; Lin, CJ; Lin, TL; Liu, AY; Wang, JT | 1 |
| Blasi, F | 2 |
| Elkhatib, WF; Noreddin, AM | 1 |
| Haftbaradaran, A; Mokabberi, R; Ravakhah, K | 1 |
| Chen, CC; Fisher, AC; Hess, G; Hill, JW; Mody, S; Raut, MK; Schein, JR | 1 |
| Bobyleva, ZD; Leshchenko, IV | 1 |
| Schafer, KR; Wispelwey, B | 1 |
| Liu, CY; Salloum, R; Weise, AM | 1 |
| Borroni, G; Castello, M; Dal Canton, A; Esposito, P; Gregorini, M; Rampino, T; Rosso, R | 1 |
| Drokov, MIu; Galstian, GM; Giliazitdinova, EA; Karpova, TI; Katrysh, SA; Kliasova, GA; Marakusha, BI; Tartakovskiĭ, IS | 1 |
| Chen, WJ; Chuang, CP; Chuang, TY; Hsueh, PR; Jong, YS; Lee, SW; Lin, CJ | 1 |
| Biedenbach, DJ; Farrell, DJ; Flamm, RK; Jones, RN; Liverman, LC; McIntyre, G | 1 |
| Inoko, H; Ishii, Y; Kimura, S; Kouyama, Y; Mitsunaga, S; Mori, N; Tateda, K; Yamaguchi, K; Yoshihara, E | 1 |
| Chang, JH; Kim, JH; Kim, SW; Lee, JH; Ryu, YJ | 1 |
| Babinchak, T; Cooper, AC; Gardiner, D; Ramirez, JA; Wiemken, T | 1 |
| Dong, LY; Jiang, Q; Wang, CY; Wu, CQ; Zhang, ZF | 1 |
| Cabré, X; Falguera, M; Ferrer, G; Pérez, J; Ruiz, A; Sacristán, O; Vallverdú, M | 1 |
| Iakovlev, SV; Iakovlev, VP | 1 |
| Díaz de Tuesta Chow-Quan, AM; Dimas Nuñez, JF; Geijo Martínez, MP; Gómez Criado, C; Herranz, CR; Saiz García, F | 1 |
| Malcolm, C; Marrie, TJ | 1 |
| Boulanger, BR; Fogarty, C; Fowler, C; Kahn, JB; Morgan, N; Oross, M; Tennenberg, A; West, M; Wiesinger, B; Wu, SC | 1 |
| Burgmann, H; Kumbein, F; Lukas, A; Mayer, B; Oberbauer, R | 1 |
| Baldassarre, M; Brollo, L; Cusenza, A; Di Qual, E; Furlanut, M; Pea, F | 1 |
| Forrest, A; Paladino, JA; Schentag, JJ; Sunderlin, JL | 1 |
| Bille, J; Bochud, PY; Calandra, T; Cometta, A; Erard, V; Lamy, O | 1 |
| Baldassarre, M; Brollo, L; Di Qual, E; Furlanut, M; Nascimben, E; Pavan, F; Pea, F | 1 |
| Corrado, M; Drusano, GL; Fowler, C; Kahn, J; Preston, SL; Weisinger, B | 1 |
| Dunbar, LM; Kahn, JB; Khashab, MM; Tennenberg, AM; Xiang, JX; Zadeikis, N | 1 |
| Martinez, FJ | 1 |
| Bernabo, J; Eiguchi, K; Farinati, A; Miller, RD; Molestina, RE; Ramirez, JA; Summersgill, JT; Uriarte, SM | 1 |
| Furlanut, M; Pea, F | 1 |
| Alvarez Lerma, F | 1 |
| Marrie, TJ | 1 |
| File, TM | 1 |
| File, TM; Khashab, MM; Milkovich, G; Tennenberg, AM; Xiang, JX; Zadeikis, N | 1 |
| Calandra, T; Cometta, A; Erard, V; Lamy, O; Wasserfallen, JB | 1 |
| Abdulla, RH; Amsden, GW; Andrews, CP; de Caprariis, PJ; Knirsch, CA; Lode, H; Mandell, LA; McIvor, A; Niederman, MS; Vrooman, PS; Zervos, M | 1 |
| González-Granda, D; Labrador, T; Martínez, I; Nieto, A; Querol-Borrás, JM; Querol-Ribelles, JM; Tenías, JM | 1 |
| Allaouchiche, B; Boselli, E; Breilh, D; Chassard, D; Djabarouti, S; Rimmelé, T; Saux, MC | 1 |
| Lüthje, P; Nurmi, I; Nyyssönen, T | 1 |
| Carratalà, J; Castellsagué, X; Dorca, J; Fernández-Agüera, A; Fernández-Sabé, N; Gudiol, F; Manresa, F; Martínez, J; Ortega, L; Rosón, B; Verdaguer, R | 1 |
| Kollef, MH; Shorr, AF; Susla, GB | 1 |
| Jackson, WL; Kollef, MH; Ramage, AS; Shorr, AF; Tennenberg, AM; Wu, SC; Zadeikis, N | 1 |
| Carratalà, J; Dorca, J; Fernández-Sabé, N; Gudiol, F; Manresa, F; Mykietiuk, A; Verdaguer, R | 1 |
| Armstrong, EP; Malone, DC; Ramachandran, S; Skrepnek, GH | 1 |
| Bédos, JP; Caulin, E; Leroy, O; Saux, P | 1 |
| Bédos, JP; Moine, P | 1 |
| Harnett, J; Matchar, DB; Samsa, GP; Wilson, J | 1 |
| Anzueto, A; Choudhri, S; Dimarco, JP; Morganroth, J; Niederman, MS | 1 |
| Anzueto, A; Choudhri, SH; Heyder, A; Niederman, MS; Pearle, J; Restrepo, MI | 1 |
| Alvarez-Beltrán, M; Alvarez-Lerma, F; Grau, S | 1 |
| Davis, NB; Kahn, J; Tennenberg, AM; Wu, SC | 1 |
| Kahn, JB; Khashab, MM; Shorr, AF; Tennenberg, AM; Xiang, JX | 1 |
| Barth, J; Hochhaus, G; Jäger, D; Kaufmann, S; Tayab, ZR | 1 |
| Krause, R; Laferl, H; Széll, M; Wenisch, C | 1 |
| Bassetti, M; Di Biagio, A; Fasce, R; Mannelli, S; Marchetti, F; Pallavicini, FB; Righi, E; Rosso, R; Viscoli, C | 1 |
| Chazan, R; Grabczak, M; Karwat, KJ | 1 |
| Boyle, MP; Brass-Ernst, L; Diener-West, M; Lee, CKK; Noschese, M; Zeitlin, PL | 1 |
| Grupper, M; Potasman, I | 1 |
| Benson, CJ; Doshi, D; Grant, R; Riedel, AA; Schein, JR; Sikirica, V; Ye, X; Zarotsky, V | 1 |
| Evers, T; Holman, A; Lloyd, A | 1 |
| Arvis, P; Carlet, J; Choudhri, S; Garau, J; Kureishi, A; Le Berre, MA; Lode, H; Read, RC; Torres, A; Winter, J | 1 |
| Doshi, D; Grant, R; Janagap-Benson, C; Olson, W; Schein, J; Sikirica, V | 1 |
| Dunbar, L; File, TM; Kohler, R; Kojak, C; Player, R; Rubin, A; Segreti, J; Williams, RR | 1 |
| Ishida, H; Ishida, Y; Kobayashi, H; Kurosaka, Y; Otani, T; Sato, K | 1 |
| Norrby, SR; Petermann, W; Salewski, E; Vetter, N; Willcox, PA | 1 |
| Barrett, T; DiPersio, JR; Doern, GV; Jones, RN; Pfaller, MA | 1 |
| Ariza, H; Ascoli, M; Casellas, JM; Dolmann, A; Gilardoni, M; Goldberg, M; Ivanovic, S; Montero, JM; Orduna, M; Tome, G | 1 |
| Maskell, JP; Sefton, AM; Williams, JD | 1 |
| Arancibia, F; Maldonado, A; Torres, A | 1 |
| Idrahim, KY; Lima Nicodemo, E; Nicodemo, AC | 1 |
| Hammerschlag, MR; Roblin, PM | 1 |
| Dulisse, B; Henke, CJ; Kojak, C; Martens, LL; Parasuraman, B; Potter, L; Rittenhouse, BE; Stinnett, AA; Williams, RR | 1 |
| Bryskier, A; Carbon, C; Farinotti, R; Joly-Guillou, ML; Wolff, M | 1 |
| Feagan, BG; Lau, CY; Marrie, TJ; Wheeler, SL; Wong, CJ | 1 |
| Shah, PM | 1 |
| Bell, T; Benenson, R; Kellogg, J; Manzella, J; Pellerin, G; Pope, D; Robertson, M | 1 |
| Scheen, AJ | 1 |
| Budanov, SV; Smirnova, LB; Vasil'ev, AN | 1 |
| Bai, Y; Lin, Y; Su, W; Xu, Z | 1 |
16 review(s) available for levofloxacin and Bacterial Pneumonia
| Article | Year |
|---|---|
The potential role of nemonoxacin for treatment of common infections.
Topics: Anti-Bacterial Agents; Chlamydia Infections; Clostridium Infections; Community-Acquired Infections; Drug Therapy, Combination; Gonorrhea; Humans; Levofloxacin; Pneumonia, Bacterial; Quinolones; Skin Diseases, Bacterial | 2015 |
[Present aspects and prospects of levofloxacin use in therapy of nosocomial pneumonia].
Topics: Anti-Bacterial Agents; Cross Infection; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial | 2008 |
[Clinical positioning of levofloxacin in the treatment of nosocomial pneumonia].
Topics: Anti-Bacterial Agents; Cross Infection; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial | 2008 |
[Therapeutic experience with levofloxacin in pneumonia and COPD].
Topics: Algorithms; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Cross Infection; Disease Susceptibility; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Levofloxacin; Multicenter Studies as Topic; Ofloxacin; Pneumonia, Bacterial; Pulmonary Disease, Chronic Obstructive; Recurrence; Treatment Outcome | 2009 |
Levofloxacin in the treatment of community-acquired pneumonia.
Topics: Aged; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Bacterial; Treatment Outcome | 2010 |
Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Topics: Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumonia, Bacterial; Primary Health Care; Quinolines; Streptococcus pneumoniae | 2010 |
[Levofloxacin in the treatment of respiratory infections].
Topics: Acute Disease; Anti-Infective Agents; Bronchitis, Chronic; Clinical Trials as Topic; Drug Resistance, Bacterial; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Respiratory Tract Infections; Sinusitis | 2002 |
Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients.
Topics: Administration, Oral; Anti-Infective Agents; Area Under Curve; Biological Availability; Case-Control Studies; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Maximum Tolerated Dose; Ofloxacin; Pneumonia, Bacterial; Reference Values; Respiratory Tract Infections | 2004 |
Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs).
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Follow-Up Studies; Humans; Infusions, Intravenous; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Treatment Outcome | 2004 |
New insights in the treatment by levofloxacin.
Topics: Anti-Infective Agents; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fluoroquinolones; Guidelines as Topic; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial | 2004 |
Quinolones for treatment of nosocomial pneumonia: a meta-analysis.
Topics: Anti-Infective Agents; Cilastatin; Ciprofloxacin; Cross Infection; Humans; Imipenem; Levofloxacin; Meta-Analysis as Topic; Ofloxacin; Pneumonia, Bacterial; Quinolones; Randomized Controlled Trials as Topic | 2005 |
Levofloxacin in the treatment of ventilator-associated pneumonia.
Topics: Anti-Infective Agents; Cross Infection; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Respiration, Artificial | 2006 |
Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Microbial; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Assessment; Risk Factors; Treatment Outcome | 2006 |
[Clinical experience of levofloxacin in community acquired pneumonia].
Topics: Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microbial; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Risk Factors | 1999 |
The use of levofloxacin in the treatment of respiratory tract infection.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infections; Haemophilus Infections; Haemophilus influenzae; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Respiratory Tract Infections; Streptococcus pneumoniae | 2000 |
[The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
Topics: Acute Disease; Animals; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infections; Humans; Levofloxacin; Maxillary Sinusitis; Ofloxacin; Pneumonia, Bacterial; Respiratory Tract Infections; Urinary Tract Infections | 2001 |
46 trial(s) available for levofloxacin and Bacterial Pneumonia
| Article | Year |
|---|---|
Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Microbial Viability; Middle Aged; Pneumonia, Bacterial; Quinolones; Safety; Treatment Outcome | 2019 |
Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Community-Acquired Infections; Double-Blind Method; Female; Humans; Levofloxacin; Macrolides; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Treatment Outcome; Triazoles; Young Adult | 2013 |
Efficacy and safety of levofloxacin in patients with bacterial pneumonia evaluated according to the new "Clinical Evaluation Methods for New Antimicrobial Agents to Treat Respiratory Infections (Second Version)".
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Female; Humans; Japan; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Prospective Studies | 2014 |
A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; China; Community-Acquired Infections; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome; Young Adult | 2014 |
A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Haemophilus influenzae; Humans; Levofloxacin; Male; Middle Aged; Mycoplasma pneumoniae; Pneumonia, Bacterial; Quinolones; Streptococcus pneumoniae; Treatment Outcome; Young Adult | 2017 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial Infections; Haemophilus Infections; Humans; Levofloxacin; Liver Function Tests; Male; Middle Aged; Minocycline; Ofloxacin; Pneumococcal Infections; Pneumonia, Bacterial; Tigecycline; Treatment Outcome | 2008 |
Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Haemophilus influenzae; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Moraxella catarrhalis; Multivariate Analysis; Ofloxacin; Pneumonia, Bacterial; Streptococcus pneumoniae; Tigecycline; Treatment Outcome | 2009 |
Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Humans; International Agencies; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Safety; Tigecycline; Treatment Outcome | 2008 |
Levofloxacin for the treatment of pneumonia caused by Streptococcus pneumoniae including multidrug-resistant strains: pooled analysis.
Topics: Aged; Anti-Bacterial Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pneumonia, Bacterial | 2009 |
Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Minocycline; Nausea; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Severity of Illness Index; Tigecycline; Treatment Outcome; Vomiting; Young Adult | 2009 |
Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Doxycycline; Drug Costs; Female; Follow-Up Studies; Humans; Length of Stay; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2010 |
High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies | 2012 |
Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Minocycline; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Tigecycline; Treatment Outcome | 2012 |
[Community-acquired pneumonia: usefulness of clinical presentation in the selection of antibiotic treatment].
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Community-Acquired Infections; Female; Hospitalization; Humans; Length of Stay; Levofloxacin; Male; Middle Aged; Ofloxacin; Penicillins; Pneumonia, Bacterial; Treatment Outcome | 2002 |
[Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization].
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Clavulanic Acid; Community-Acquired Infections; Drug Therapy, Combination; Female; Hospitalization; Humans; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2002 |
Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
Topics: Adult; Aged; Anti-Bacterial Agents; Cilastatin; Ciprofloxacin; Cross Infection; Drug Therapy, Combination; Female; Humans; Imipenem; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Prospective Studies; Pseudomonas aeruginosa | 2003 |
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.
Topics: Aged; Anti-Infective Agents; Chromatography, High Pressure Liquid; Critical Illness; Cross Infection; Female; Humans; Injections, Intravenous; Intensive Care Units; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Time Factors; Ventilators, Mechanical | 2003 |
Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Area Under Curve; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2003 |
Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hospitalization; Hospitals, Teaching; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pilot Projects; Pneumonia, Bacterial; Probability; Prospective Studies; Risk Assessment; Statistics, Nonparametric; Treatment Outcome | 2004 |
Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Cross Infection; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Methicillin Resistance; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcus aureus; Treatment Outcome | 2004 |
Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
Topics: Adult; Anti-Bacterial Agents; Chlamydia Infections; Chlamydophila pneumoniae; Community-Acquired Infections; Double-Blind Method; Drug Administration Schedule; Female; Humans; Legionnaires' Disease; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Pneumonia, Mycoplasma | 2004 |
Clinical experience with levofloxacin in the treatment of pneumonia in ICU patients.
Topics: Anti-Infective Agents; Confidence Intervals; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospital Mortality; Humans; Infusions, Intravenous; Intensive Care Units; Levofloxacin; Male; Microbial Sensitivity Tests; Odds Ratio; Ofloxacin; Pneumonia, Bacterial; Prognosis; Risk Assessment; Spain; Treatment Outcome | 2004 |
Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Azithromycin; Cefuroxime; Community-Acquired Infections; Critical Pathways; Drug Therapy, Combination; Female; Humans; Levofloxacin; Longitudinal Studies; Male; Middle Aged; Ofloxacin; Oxygen Inhalation Therapy; Pneumococcal Infections; Pneumonia; Pneumonia, Bacterial; Treatment Outcome | 2004 |
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Community-Acquired Infections; Drug Administration Schedule; Drug Costs; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; Treatment Outcome | 2004 |
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2004 |
Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Azithromycin; Canada; Ceftriaxone; Community-Acquired Infections; Drug Administration Schedule; Female; Germany; Humans; Infusions, Intravenous; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; Severity of Illness Index; Treatment Outcome; United States | 2004 |
Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
Topics: Aged; Anti-Bacterial Agents; Ceftriaxone; Clarithromycin; Cohort Studies; Community-Acquired Infections; Drug Therapy, Combination; Female; Hospitalization; Humans; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2005 |
Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia.
Topics: Aged; Anti-Bacterial Agents; Capillary Permeability; Community-Acquired Infections; Creatinine; Critical Care; Diffusion; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Hospital Mortality; Humans; Infusions, Intravenous; Levofloxacin; Lung; Male; Metabolic Clearance Rate; Middle Aged; Ofloxacin; Pneumonia, Bacterial | 2005 |
Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Bacterial Agents; Community-Acquired Infections; Female; Follow-Up Studies; Hospitalization; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Outcome Assessment, Health Care; Patient Satisfaction; Pneumonia, Bacterial; Quality of Life; Risk Factors | 2005 |
Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial.
Topics: Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Cohort Studies; Cross Infection; Double-Blind Method; Drug Combinations; Drug Resistance, Bacterial; Female; Humans; Imipenem; Levofloxacin; Male; Middle Aged; Multivariate Analysis; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Thienamycins; Treatment Outcome; Ventilators, Mechanical | 2005 |
Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, Bacterial; Female; Humans; Legionnaires' Disease; Levofloxacin; Macrolides; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Time Factors | 2005 |
Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefotaxime; Chi-Square Distribution; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Intensive Care Units; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2005 |
A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Community-Acquired Infections; Costs and Cost Analysis; Drug Therapy, Combination; Female; Home Care Services; Hospitalization; Humans; Length of Stay; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; United States | 2005 |
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Comorbidity; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Heart Conduction System; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines | 2005 |
Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Safety | 2006 |
Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Community-Acquired Infections; Drug Administration Schedule; Hospitalization; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Retrospective Studies; Severity of Illness Index; Streptococcus pneumoniae; Treatment Outcome | 2006 |
Do intensive care patients need an individualized dosing regimen for levofloxacin?
Topics: Anti-Bacterial Agents; Critical Illness; Female; Humans; Intensive Care Units; Levofloxacin; Male; Middle Aged; Models, Biological; Ofloxacin; Pancreatitis; Pneumonia, Bacterial; Sepsis | 2006 |
Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Doxycycline; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitalization; Humans; Levofloxacin; Macrolides; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Treatment Failure | 2006 |
Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit.
Topics: Aged; Anti-Bacterial Agents; Ceftazidime; Cross Infection; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Italy; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Treatment Outcome | 2006 |
Levofloxacin pharmacokinetics in adult cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Kidney Function Tests; Levofloxacin; Male; Metabolic Clearance Rate; Ofloxacin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum | 2007 |
A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Topics: Administration, Oral; Aza Compounds; Ceftriaxone; Community-Acquired Infections; Cost of Illness; Cost-Benefit Analysis; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Hospitalization; Humans; Infusions, Intravenous; Length of Stay; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2008 |
Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Ceftriaxone; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2008 |
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prodrugs; Prospective Studies; Treatment Outcome | 1997 |
A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitalization; Humans; International Cooperation; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Treatment Outcome | 1998 |
An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.
Topics: Adult; Aged; Ambulatory Care; Anti-Infective Agents; Cefuroxime; Cephalosporins; Drug Costs; Evaluation Studies as Topic; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies | 2000 |
Predictors of symptom resolution in patients with community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gastrointestinal Diseases; Humans; Levofloxacin; Male; Middle Aged; Multivariate Analysis; Ofloxacin; Pneumonia, Bacterial; Predictive Value of Tests; Treatment Outcome | 2000 |
53 other study(ies) available for levofloxacin and Bacterial Pneumonia
| Article | Year |
|---|---|
Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitalization; Humans; Length of Stay; Macrolides; Male; Middle Aged; New York; Pneumonia, Bacterial; Retrospective Studies; Treatment Outcome; Veterans | 2007 |
Pharmacological effects and mechanism of Maxing Shigan decoction in the treatment of Pseudomonas aeruginosa pneumonia.
Topics: Animals; Drugs, Chinese Herbal; Levofloxacin; Lung; Male; Mice; Mice, Inbred BALB C; Pneumonia, Bacterial; Pseudomonas aeruginosa | 2024 |
Topics: Anti-Bacterial Agents; Azithromycin; Bronchoalveolar Lavage Fluid; Carrier State; Child, Preschool; Drug Resistance, Bacterial; Female; Humans; Levofloxacin; Mycoplasma pneumoniae; Pneumonia, Bacterial; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA, Ribosomal, 23S | 2019 |
Synergistic effect of chlorogenic acid and levofloxacin against Klebsiella pneumonia infection in vitro and in vivo.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Chlorogenic Acid; Drug Resistance, Bacterial; Drug Synergism; Inflammation Mediators; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Lung; Male; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Pneumonia, Bacterial | 2020 |
Chryseobacterium indolegenes infection in a patient with chronic obstructive pulmonary disease.
Topics: Aged; Anti-Bacterial Agents; C-Reactive Protein; Chryseobacterium; Culture Techniques; Flavobacteriaceae Infections; Humans; Levofloxacin; Male; Pneumonia, Bacterial; Pulmonary Disease, Chronic Obstructive; Sputum | 2017 |
Association between oral fluoroquinolone use and lateral canthal tendon rupture: case report.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Blepharoplasty; Ciprofloxacin; Conjunctival Diseases; Drug Therapy, Combination; Ectropion; Female; Humans; Levofloxacin; Pneumonia, Bacterial; Rupture; Suture Techniques; Tendon Injuries | 2018 |
Impact of an antimicrobial stewardship program on outcomes in patients with community-acquired pneumonia admitted to a tertiary community hospital.
Topics: Aged; Anti-Bacterial Agents; Antimicrobial Stewardship; Azithromycin; Ceftriaxone; Community-Acquired Infections; Female; Hospitals, Community; Humans; Length of Stay; Levofloxacin; Male; Pneumonia, Bacterial; Retrospective Studies; Tertiary Care Centers; Treatment Outcome | 2018 |
Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Hospital Mortality; Hospitalization; Humans; Japan; Levofloxacin; Male; Middle Aged; Pneumonia, Bacterial; Severity of Illness Index; Treatment Outcome | 2019 |
Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Levofloxacin; Mice; Mice, Inbred C57BL; Mutant Proteins; Pneumonia, Bacterial; Treatment Outcome | 2013 |
Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; APACHE; Cross Infection; Drug Resistance, Microbial; Female; Fluoroquinolones; Hospital Mortality; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Virulence | 2014 |
Risk screening for long QT prior to prescribing levofloxacin.
Topics: Aged; Anti-Bacterial Agents; Contraindications; Electrocardiography; Emergency Service, Hospital; Female; Humans; Levofloxacin; Long QT Syndrome; Pneumonia, Bacterial; Risk Factors; Torsades de Pointes | 2014 |
A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
Topics: Acinetobacter baumannii; Aged; Aged, 80 and over; Anti-Bacterial Agents; C-Reactive Protein; Carbapenems; Cefoperazone; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Humans; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Minocycline; Pneumonia, Bacterial; Retrospective Studies; Sulbactam; Thienamycins | 2014 |
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Female; Fluoroquinolones; Follow-Up Studies; Humans; Levofloxacin; Linear Models; Longitudinal Studies; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Mycobacterium tuberculosis; Ofloxacin; Pneumonia, Bacterial; Taiwan; Tuberculosis, Pulmonary; Young Adult | 2015 |
[Prospects of Levofloxacin Use in Therapy of Patients with Bronchopulmonary Diseases or Skin and Soft Tissue Pyo-Inflammatory Lesions].
Topics: Adult; Anti-Bacterial Agents; Bronchitis; Dose-Response Relationship, Drug; Female; Humans; Levofloxacin; Lung Diseases; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Severity of Illness Index; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult | 2014 |
Community-acquired bacteremic Streptomyces atratus pneumonia in animmunocompetent adult: a case report.
Topics: Actinomycetales Infections; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Bronchoscopy; Community-Acquired Infections; Humans; Imipenem; Immunocompetence; Levofloxacin; Male; Pneumonia, Bacterial; Sequence Analysis, DNA; Streptomyces; Treatment Outcome | 2015 |
Does Critical Illness Change Levofloxacin Pharmacokinetics?
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Critical Illness; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Middle Aged; Models, Theoretical; Monte Carlo Method; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections | 2015 |
A case of lobar pneumonia and sepsis with death caused by invasive Klebsiella rhinoscleromatis infection.
Topics: Aged; Anti-Bacterial Agents; Blood Culture; C-Reactive Protein; Diabetes Mellitus, Type 2; Fatal Outcome; Humans; Klebsiella Infections; Klebsiella pneumoniae; Leukocyte Count; Levofloxacin; Lung; Male; Pneumonia, Bacterial; Shock, Septic; Tomography, X-Ray Computed | 2016 |
In vitro activity of levofloxacin against planktonic and biofilm Stenotrophomonas maltophilia lifestyles under conditions relevant to pulmonary infection in cystic fibrosis, and relationship with SmeDEF multidrug efflux pump expression.
Topics: Anti-Bacterial Agents; Biofilms; Cystic Fibrosis; Gene Expression Regulation, Bacterial; Genes, MDR; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Pneumonia, Bacterial; Stenotrophomonas maltophilia | 2016 |
Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Bacterial; Female; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Bacterial; Porins | 2008 |
Sepsis caused by Elizabethkingia miricola successfully treated with tigecycline and levofloxacin.
Topics: Anti-Bacterial Agents; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Lymphoma, Mantle-Cell; Male; Middle Aged; Minocycline; Ofloxacin; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sepsis; Stem Cell Transplantation; Tigecycline | 2008 |
Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Community-Acquired Infections; Doxycycline; Drug Resistance, Multiple, Bacterial; Humans; Kentucky; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Respiratory Tract Infections; Streptococcus pneumoniae; Treatment Outcome; United States | 2002 |
Rapidly fatal bacteremic pneumonia caused by Klebsiella pneumoniae with K1 hypermucoviscosity phenotype in a previously healthy young man receiving levofloxacin treatment.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Bacteremia; Bacterial Capsules; Bacterial Typing Techniques; Fatal Outcome; Humans; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Multiple Organ Failure; Ofloxacin; Phenotype; Pneumonia, Bacterial; Polysaccharides, Bacterial; Serotyping; Shock, Septic; Young Adult | 2009 |
Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cohort Studies; Community-Acquired Infections; Female; Humans; Insurance Claim Review; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Retrospective Studies; Risk Factors; Treatment Failure | 2010 |
[Clinical features and delayed aftereffects of Legionellosis pneumonia during an epidemic outbreak].
Topics: Anti-Bacterial Agents; Azithromycin; Disease Outbreaks; Female; Humans; Legionellosis; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Russia; Treatment Outcome; Water Supply | 2010 |
Possible case of levofloxacin-induced thrombocytopenia.
Topics: Aged; Anti-Bacterial Agents; Carcinoma, Squamous Cell; Female; Humans; Levofloxacin; Mouth Neoplasms; Ofloxacin; Platelet Count; Pneumonia, Bacterial; Thrombocytopenia | 2011 |
Erythema nodosum in kidney transplant recipient: a rare complication of pneumonia treatment.
Topics: Adult; Anti-Bacterial Agents; Erythema Nodosum; Female; Humans; Kidney Transplantation; Leg; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Skin | 2012 |
[A case of legionellesis pneumonia verified by isolation of Legionella pneumophila serogroup 1 from bronchoalveolar lavage fluid treated with levofloxacine and tigecycline].
Topics: Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Drug Therapy, Combination; Humans; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Male; Middle Aged; Minocycline; Ofloxacin; Pneumonia, Bacterial; Tigecycline; Treatment Outcome | 2011 |
Rapidly fatal community-acquired pneumonia due to Klebsiella pneumoniae complicated with acute myocarditis and accelerated idioventricular rhythm.
Topics: Accelerated Idioventricular Rhythm; Acidosis, Lactic; Acute Disease; Community-Acquired Infections; Electrocardiography; Fatal Outcome; Humans; Intensive Care Units; Klebsiella pneumoniae; Levofloxacin; Male; Middle Aged; Myocarditis; Ofloxacin; Pneumonia, Bacterial; Shock, Septic | 2012 |
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Geography; Haemophilus influenzae; Humans; Inhibitory Concentration 50; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Streptococcus pneumoniae | 2012 |
A peptide based on homologous sequences of the β-barrel assembly machinery component BamD potentiates antibiotic susceptibility of Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Bacterial Outer Membrane Proteins; Blotting, Western; Colistin; Disease Models, Animal; Drug Therapy, Combination; Electrophoresis, Polyacrylamide Gel; Female; Levofloxacin; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Ofloxacin; Peptides; Pneumonia, Bacterial; Protein Binding; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2012 |
[Protection and mechanism of Fagopyrum cymosum on lung injury in rats with Klebsiella pneumonia].
Topics: Animals; Chemokine CXCL2; Cytokines; Disease Models, Animal; Drugs, Chinese Herbal; Fagopyrum; Immunohistochemistry; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Lung; Male; Ofloxacin; Pneumonia, Bacterial; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2012 |
Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.
Topics: Adolescent; Adult; Aged; Alberta; Ambulatory Care; Analysis of Variance; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Emergency Service, Hospital; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2003 |
The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Child; Child, Preschool; Chlamydophila Infections; Chlamydophila pneumoniae; Cluster Analysis; Cohort Studies; Community-Acquired Infections; Comorbidity; Female; Haemophilus Infections; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Respiratory Tract Infections; Treatment Outcome | 2003 |
Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia.
Topics: Adult; Aged; Biological Availability; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Intensive Care Units; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Probability; Respiration, Artificial; Risk Assessment; Sampling Studies; Sensitivity and Specificity; Treatment Outcome | 2003 |
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitalization; Humans; Levofloxacin; Macrolides; Moxifloxacin; Naphthyridines; Ofloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Quinolines; Retrospective Studies | 2004 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Movement; Chemokines; Chlamydia; Endothelial Cells; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Monocytes; Moxifloxacin; Neutrophils; Ofloxacin; Phagocytes; Pneumonia, Bacterial; Quinolines; Stimulation, Chemical; Tumor Necrosis Factor-alpha; Umbilical Veins | 2004 |
Missed Achilles tendon rupture due to oral levofloxacin: surgical treatment and result.
Topics: Achilles Tendon; Administration, Oral; Anti-Bacterial Agents; Diagnostic Errors; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Orthopedic Procedures; Pneumonia, Bacterial; Rupture; Treatment Outcome | 2005 |
An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Databases as Topic; Erythromycin; Female; Health Care Costs; Humans; Levofloxacin; Male; Managed Care Programs; Middle Aged; Models, Econometric; Ofloxacin; Pneumonia, Bacterial; Retrospective Studies; Risk Assessment; Treatment Outcome | 2005 |
Levofloxacin for treatment of ventilator-associated pneumonia: putting the cart before the horse.
Topics: Anti-Bacterial Agents; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Ventilators, Mechanical | 2005 |
[Efficacy and safety of levofloxacin treatment of community--acquired pneumonia in hospitalized patients].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Radiography; Treatment Outcome | 2006 |
Fluoroquinolones in community-acquired pneumonia when tuberculosis is around: an instructive case.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Levofloxacin; Male; Mycobacterium tuberculosis; Ofloxacin; Pneumonia, Bacterial; Radiography; Tuberculosis, Pulmonary | 2008 |
Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis; Databases as Topic; Drug Costs; Drug Utilization; Emergency Service, Hospital; Female; Health Care Costs; Health Resources; Hospital Costs; Humans; Insurance Claim Reporting; Levofloxacin; Logistic Models; Macrolides; Male; Managed Care Programs; Middle Aged; Odds Ratio; Ofloxacin; Pneumonia, Bacterial; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Failure | 2008 |
A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Comorbidity; Female; Fluoroquinolones; Health Care Costs; Hospitalization; Humans; Infusions, Intravenous; Insurance Claim Review; Length of Stay; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Research Design; Retrospective Studies; Treatment Outcome; United States | 2008 |
In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa.
Topics: Alginates; Animals; Anti-Infective Agents; Biofilms; Female; Glucuronic Acid; Guinea Pigs; Hexuronic Acids; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Permeability; Pneumonia, Bacterial; Polytetrafluoroethylene; Pseudomonas aeruginosa; Pseudomonas Infections | 1998 |
Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY Antimicrobial Surveillance Program (1998).
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Microbial; Humans; Immunocompromised Host; Levofloxacin; Male; Microbial Sensitivity Tests; Moraxella catarrhalis; Neisseriaceae Infections; Ofloxacin; Pneumonia, Bacterial; Population Surveillance | 1998 |
Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Bronchitis; Chronic Disease; Community-Acquired Infections; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Middle Aged; Moraxella catarrhalis; Ofloxacin; Penicillin Resistance; Pneumonia, Bacterial; Pseudomonas aeruginosa; Streptococcus pneumoniae | 1999 |
Selection of resistant variants of respiratory pathogens by quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Nalidixic Acid; Ofloxacin; Pneumonia, Bacterial; Streptococcus pneumoniae | 1999 |
Oral levofloxacin in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Community-Acquired Infections; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial | 2000 |
Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Chlamydia Infections; Chlamydophila pneumoniae; Community-Acquired Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial | 2000 |
In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia.
Topics: Acinetobacter Infections; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Area Under Curve; Disease Models, Animal; Drug Therapy, Combination; Female; Imipenem; Levofloxacin; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Bacterial; Thienamycins | 2000 |
Choice of antibiotic and risk of colonization with vancomycin-resistant Enterococcus among patients admitted for treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Enterococcus; Erythromycin; Female; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Risk Factors; Vancomycin Resistance | 2000 |
[Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
Topics: Acute Disease; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Bronchitis; Community-Acquired Infections; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Sinusitis; Urinary Tract Infections | 2000 |
Clinical effects and bronchoalveolar transfer of levofloxacin in patients with community-acquired pneumonia.
Topics: Adult; Aged; Anti-Infective Agents; Bacteria; Bronchoalveolar Lavage Fluid; Community-Acquired Infections; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Time Factors; Treatment Outcome | 2001 |